148 related articles for article (PubMed ID: 22172035)
1. HDAC inhibitor trichostatin A suppresses osteoclastogenesis by upregulating the expression of C/EBP-β and MKP-1.
Williams PJ; Nishu K; Rahman MM
Ann N Y Acad Sci; 2011 Dec; 1240(1):18-25. PubMed ID: 22172035
[TBL] [Abstract][Full Text] [Related]
2. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Kim HN; Ha H; Lee JH; Jung K; Yang D; Woo KM; Lee ZH
Eur J Pharmacol; 2009 Nov; 623(1-3):22-9. PubMed ID: 19766111
[TBL] [Abstract][Full Text] [Related]
3. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages.
Rahman MM; Kukita A; Kukita T; Shobuike T; Nakamura T; Kohashi O
Blood; 2003 May; 101(9):3451-9. PubMed ID: 12511413
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of C/EBPβ and TSC2 by an HDAC inhibitor CG200745 protects heart from DOCA-induced hypertrophy.
Lee E; Lee HA; Kim M; Do GY; Cho HM; Kim GJ; Jung H; Song JH; Cho JM; Kim I
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):226-236. PubMed ID: 30099761
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro.
Cantley MD; Fairlie DP; Bartold PM; Rainsford KD; Le GT; Lucke AJ; Holding CA; Haynes DR
J Cell Physiol; 2011 Dec; 226(12):3233-41. PubMed ID: 21344383
[TBL] [Abstract][Full Text] [Related]
6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
7. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice.
Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH
Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
9. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of LPS-induced C/EBP delta by trichostatin A has a positive effect on LPS-induced cyclooxygenase 2 expression in RAW264.7 cells.
Liu YW; Wang SA; Hsu TY; Chen TA; Chang WC; Hung JJ
J Cell Biochem; 2010 Aug; 110(6):1430-8. PubMed ID: 20506344
[TBL] [Abstract][Full Text] [Related]
11. Protection against reperfusion lung injury via aborgating multiple signaling cascades by trichostatin A.
Hsu HH; Wu SY; Tang SE; Wu GC; Li MH; Huang KL; Chu SJ
Int Immunopharmacol; 2015 Apr; 25(2):267-75. PubMed ID: 25698558
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
14. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.
Yamashita T; Yao Z; Li F; Zhang Q; Badell IR; Schwarz EM; Takeshita S; Wagner EF; Noda M; Matsuo K; Xing L; Boyce BF
J Biol Chem; 2007 Jun; 282(25):18245-18253. PubMed ID: 17485464
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.
Ooi JY; Tuano NK; Rafehi H; Gao XM; Ziemann M; Du XJ; El-Osta A
Epigenetics; 2015; 10(5):418-30. PubMed ID: 25941940
[TBL] [Abstract][Full Text] [Related]
17. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
18. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
[TBL] [Abstract][Full Text] [Related]
19. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of osteoclastogenesis by histone deacetylase inhibitor Quisinostat protects mice against titanium particle-induced bone loss.
Zhang L; Zhang L; You H; Sun S; Liao Z; Zhao G; Chen J
Eur J Pharmacol; 2021 Aug; 904():174176. PubMed ID: 34004213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
